Combined and Gene Amplification Predicts Laryngeal Cancer Risk Beyond Histopathological Grading

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Mar 13

PMID 38473941

Authors

Irene Montoro-Jimenez

Rocio Granda-Diaz

Sofia T Menendez

Llara Prieto-Fernandez

Maria Otero-Rosales

Miguel Alvarez-Gonzalez

Vanessa Garcia-de-la-Fuente

Aida Rodriguez

Juan P Rodrigo

Saul Alvarez-Teijeiro

Juana M Garcia-Pedrero

Francisco Hermida-Prado

Affiliations

Soon will be listed here.

Abstract

The and genes map at 3q26, a chromosomal region frequently amplified in head and neck cancers, which is associated with poor prognosis. This study explores the clinical significance of and gene amplification in early tumorigenesis. Gene copy number was analyzed by real-time PCR in 62 laryngeal precancerous lesions and correlated with histopathological grading and laryngeal cancer risk. Amplification of the and genes was frequently detected in 19 (31%) and 32 (52%) laryngeal dysplasias, respectively, and co-amplification in 18 (29%) cases. The and amplifications were predominant in high-grade dysplasias and significantly associated with laryngeal cancer risk beyond histological criteria. Multivariable Cox analysis further revealed gene amplification as an independent predictor of laryngeal cancer development. Interestingly, combined and amplification allowed us to distinguish three cancer risk subgroups, and and co-amplification was found the strongest predictor by ROC analysis. Our data demonstrate the clinical relevance of and amplification in early laryngeal tumorigenesis. Remarkably, amplification was found to be an independent cancer predictor. Furthermore, combined and amplification is emerging as a valuable and easy-to-implement tool for cancer risk assessment in patients with laryngeal precancerous lesions beyond current WHO histological grading.

References

Li L, Lai F, Hu X, Liu B, Lu X, Lin Z . Multifaceted SOX2-chromatin interaction underpins pluripotency progression in early embryos. Science. 2023; 382(6676):eadi5516. DOI: 10.1126/science.adi5516. View

Takacs F, Radosa J, Linxweiler M, Kasoha M, Bohle R, Bochen F . Identification of 3q oncogene SEC62 as a marker for distant metastasis and poor clinical outcome in invasive ductal breast cancer. Arch Gynecol Obstet. 2019; 299(5):1405-1413. DOI: 10.1007/s00404-019-05081-4. View

Yi M, Zhang D, Song B, Zhao B, Niu M, Wu Y . Increased expression of ECT2 predicts the poor prognosis of breast cancer patients. Exp Hematol Oncol. 2022; 11(1):107. PMC: 9791744. DOI: 10.1186/s40164-022-00361-3. View

Barsouk A, Aluru J, Rawla P, Saginala K, Barsouk A . Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma. Med Sci (Basel). 2023; 11(2). PMC: 10304137. DOI: 10.3390/medsci11020042. View

Zheng X, Gao L, Wang B, Shen P, Yuan X, Zhang L . Overexpression of EIF5A2 is associated with poor survival and aggressive tumor biology in gallbladder cancer. Histol Histopathol. 2019; 35(6):579-587. DOI: 10.14670/HH-18-186. View

Starzynska A, Adamska P, Sejda A, Sakowicz-Burkiewicz M, Adamski L, Marvaso G . Any Role of PIK3CA and PTEN Biomarkers in the Prognosis in Oral Squamous Cell Carcinoma?. Life (Basel). 2020; 10(12). PMC: 7761816. DOI: 10.3390/life10120325. View

Cheng H, Yang X, Si H, Saleh A, Xiao W, Coupar J . Genomic and Transcriptomic Characterization Links Cell Lines with Aggressive Head and Neck Cancers. Cell Rep. 2018; 25(5):1332-1345.e5. PMC: 6280671. DOI: 10.1016/j.celrep.2018.10.007. View

Shaikh T . Copy Number Variation Disorders. Curr Genet Med Rep. 2018; 5(4):183-190. PMC: 5931734. DOI: 10.1007/s40142-017-0129-2. View

Haddad R, Shin D . Recent advances in head and neck cancer. N Engl J Med. 2008; 359(11):1143-54. DOI: 10.1056/NEJMra0707975. View

10.

Marquard F, Jucker M . PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer. Biochem Pharmacol. 2019; 172:113729. DOI: 10.1016/j.bcp.2019.113729. View

11.

Zhang S, Cui W . Sox2, a key factor in the regulation of pluripotency and neural differentiation. World J Stem Cells. 2014; 6(3):305-11. PMC: 4131272. DOI: 10.4252/wjsc.v6.i3.305. View

12.

Qian J, Massion P . Role of chromosome 3q amplification in lung cancer. J Thorac Oncol. 2008; 3(3):212-5. DOI: 10.1097/JTO.0b013e3181663544. View

13.

Novak D, Huser L, Elton J, Umansky V, Altevogt P, Utikal J . SOX2 in development and cancer biology. Semin Cancer Biol. 2019; 67(Pt 1):74-82. DOI: 10.1016/j.semcancer.2019.08.007. View

14.

Dirix P, Lambrecht M, Nuyts S . Radiotherapy for laryngeal squamous cell carcinoma: current standards. Expert Rev Anticancer Ther. 2010; 10(9):1461-9. DOI: 10.1586/era.10.110. View

15.

Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo H . Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019; 380(20):1929-1940. DOI: 10.1056/NEJMoa1813904. View

16.

. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015; 517(7536):576-82. PMC: 4311405. DOI: 10.1038/nature14129. View

17.

Chow L . Head and Neck Cancer. N Engl J Med. 2020; 382(1):60-72. DOI: 10.1056/NEJMra1715715. View

18.

Rodrigo J, Alvarez-Alija G, Menendez S, Mancebo G, Allonca E, Garcia-Carracedo D . Cortactin and focal adhesion kinase as predictors of cancer risk in patients with laryngeal premalignancy. Cancer Prev Res (Phila). 2011; 4(8):1333-41. DOI: 10.1158/1940-6207.CAPR-10-0338. View

19.

Candido S, Salemi R, Piccinin S, Falzone L, Libra M . The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3K-Akt Pathways. Pharmaceutics. 2022; 14(3). PMC: 8950976. DOI: 10.3390/pharmaceutics14030590. View

20.

Mishra R, Patel H, Alanazi S, Kilroy M, Garrett J . PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects. Int J Mol Sci. 2021; 22(7). PMC: 8037248. DOI: 10.3390/ijms22073464. View